论文部分内容阅读
以英、法、德三国为代表的欧洲生物医药产业近年发展迅猛,已为世人所瞩目。为了研究和调整北京市生物医药产业的发展战略,制定适合我国国情的远期发展规划,北京市生物工程和新医药领导小组办公室一行四人,于1998年9月赴英、法、德三国考察。二十余天共参观考察了德国的Bayer制药公司、Fresenius制药公司、英国的Cantab公司、PPL公司和法国的RPR公司,英国剑桥大学国际制造中心生物化学系,以及剑桥科学园
The European bio-pharmaceutical industry, represented by Britain, France and Germany, has developed rapidly in recent years and has attracted worldwide attention. In order to study and adjust the development strategy of Beijing’s biopharmaceutical industry and formulate a long-term development plan that suits China’s national conditions, the Beijing Bioengineering and New Medicine Leading Group office has four members. In September 1998, they went to the UK, France, and Germany to inspect the country. . More than 20 days visited Germany’s Bayer Pharmaceuticals, Fresenius Pharmaceuticals, UK’s Cantab, PPL, and France’s RPR, the Department of Biochemistry at the International Manufacturing Center, Cambridge University, UK, and Cambridge Science Park